Sagent Recalls Four Lots of Levetiracetam
The antiseizure medication affected by the recall could have sterility issues.
Sagent Pharmaceuticals is recalling four lots of Levetiracetam Injection, which is used for the treatment of certain types of seizures. It is packaged in a 5 mL single-does vial and was distributed from March 2021 until November 2021.
The recall is because of a lack of container closure integrity, which could lead to sterility issues. To date, Sagent has not received reports of any product complaints or adverse events associated with this issue.
The NDC number of the affected product is 25021-780-05. The lot numbers included in the recall include:
- B0G85VB, with an expiration date of June 2022
- B0K88VA, with an expiration date of September 2022
- B0K89VA, with an expiration date of September 2022
- B1G194A, with an expiration date of June 2023
Levetiracetam label
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
